Gene Review:
CYP2C9 - cytochrome P450, family 2, subfamily C,...
Homo sapiens
Synonyms:
(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, CPC9, CYP2C, ...
Schönfelder,
Drenth,
Huybers,
Meisel,
Begg,
Peters,
Chen,
Malaplate-Armand,
Rettie,
Sugimoto,
González,
van Oijen,
Roots,
Kurland,
Malmqvist,
Verheugt,
Dorado,
Zaphiropoulos,
Ohman,
Shindo,
De La Rubia,
Jansen,
Batt,
Masson,
Visvikis-Siest,
Laheij,
Brauckhoff,
Nyström,
Karlsson,
Kudlicz,
Powell,
Lambert,
Kirchheiner,
Peñas-LLedó,
Kamada,
Preiss,
Yonezawa,
Gardiner,
Baumann,
Kurimoto,
Miyazawa,
Wilson,
Knüpfer,
Omata,
Bauer,
Wolf,
Melhus,
Horn,
Wu,
Köhler,
Meineke,
LLerena,
Kawabata,
Bloswick,
Shimada,
Furuta,
Berecz,
Schmidt,
Ferrari,
Brockmöller,
Jones,
Hallberg,
Lasker,
Lind,
Kahan,
- Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Desta, Z., Zhao, X., Shin, J.G., Flockhart, D.A. Clinical pharmacokinetics. (2002)
- Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study. Tranah, G.J., Chan, A.T., Giovannucci, E., Ma, J., Fuchs, C., Hunter, D.J. Mol. Carcinog. (2005)
- Engineering human cytochrome P450 enzymes into catalytically self-sufficient chimeras using molecular Lego. Dodhia, V.R., Fantuzzi, A., Gilardi, G. J. Biol. Inorg. Chem. (2006)
- Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. George, J., Liddle, C., Murray, M., Byth, K., Farrell, G.C. Biochem. Pharmacol. (1995)
- The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Visser, L.E., van Schaik, R.H., Jan Danser, A.H., Hofman, A., Witteman, J.C., van Duijn, C.M., Uitterlinden, A.G., Pols, H.A., Stricker, B.H. Pharmacogenet. Genomics (2007)
- CYP2C9 gene and susceptibility to major depressive disorder. LLerena, A., Berecz, R., Dorado, P., González, A.P., Peñas-LLedó, E.M., De La Rubia, A. Pharmacogenomics J. (2003)
- N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. Spielberg, S.P. Journal of pharmacokinetics and biopharmaceutics. (1996)
- Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Gardiner, S.J., Begg, E.J. Pharmacol. Rev. (2006)
- Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Rettie, A.E., Jones, J.P. Annu. Rev. Pharmacol. Toxicol. (2005)
- Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Higashi, M.K., Veenstra, D.L., Kondo, L.M., Wittkowsky, A.K., Srinouanprachanh, S.L., Farin, F.M., Rettie, A.E. JAMA (2002)
- Down-regulation of astroglial CYP2C, glucocorticoid receptor and constitutive androstane receptor genes in response to cocaine in human U373 MG astrocytoma cells. Malaplate-Armand, C., Ferrari, L., Masson, C., Visvikis-Siest, S., Lambert, H., Batt, A.M. Toxicol. Lett. (2005)
- The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Hallberg, P., Karlsson, J., Kurland, L., Lind, L., Kahan, T., Malmqvist, K., Ohman, K.P., Nyström, F., Melhus, H. J. Hypertens. (2002)
- CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Schmidt, R., Baumann, F., Knüpfer, H., Brauckhoff, M., Horn, L.C., Schönfelder, M., Köhler, U., Preiss, R. Br. J. Cancer (2004)
- Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid. van Oijen, M.G., Huybers, S., Peters, W.H., Drenth, J.P., Laheij, R.J., Verheugt, F.W., Jansen, J.B. British journal of clinical pharmacology. (2005)
- Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. O'Sullivan, T.A., Wang, J.P., Unadkat, J.D., al-Habet, S.M., Trager, W.F., Smith, A.L., McNamara, S., Aitken, M.L. Clin. Pharmacol. Ther. (1993)
- Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. Gerbal-Chaloin, S., Daujat, M., Pascussi, J.M., Pichard-Garcia, L., Vilarem, M.J., Maurel, P. J. Biol. Chem. (2002)
- RNA molecules containing exons originating from different members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis and liver. Zaphiropoulos, P.G. Nucleic Acids Res. (1999)
- Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Kirchheiner, J., Kudlicz, D., Meisel, C., Bauer, S., Meineke, I., Roots, I., Brockmöller, J. Clin. Pharmacol. Ther. (2003)
- Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. Ferguson, S.S., LeCluyse, E.L., Negishi, M., Goldstein, J.A. Mol. Pharmacol. (2002)
- Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Chang, T.K., Yu, L., Maurel, P., Waxman, D.J. Cancer Res. (1997)
- Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Dvorak, Z., Modriansky, M., Pichard-Garcia, L., Balaguer, P., Vilarem, M.J., Ulrichová, J., Maurel, P., Pascussi, J.M. Mol. Pharmacol. (2003)
- Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Treluyer, J.M., Gueret, G., Cheron, G., Sonnier, M., Cresteil, T. Pharmacogenetics (1997)
- Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Ibeanu, G.C., Goldstein, J.A. Biochemistry (1995)
- The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. Gentile, D.M., Verhoeven, C.H., Shimada, T., Back, D.J. J. Pharmacol. Exp. Ther. (1998)
- Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. Paine, M.J., McLaughlin, L.A., Flanagan, J.U., Kemp, C.A., Sutcliffe, M.J., Roberts, G.C., Wolf, C.R. J. Biol. Chem. (2003)
- Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Chainuvati, S., Nafziger, A.N., Leeder, J.S., Gaedigk, A., Kearns, G.L., Sellers, E., Zhang, Y., Kashuba, A.D., Rowland, E., Bertino, J.S. Clin. Pharmacol. Ther. (2003)
- Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries. Fisslthaler, B., Hinsch, N., Chataigneau, T., Popp, R., Kiss, L., Busse, R., Fleming, I. Hypertension (2000)
- Production of inhibitory polyclonal antibodies against cytochrome P450s. Ng, P.S., Imaoka, S., Hiroi, T., Osada, M., Niwa, T., Kamataki, T., Funae, Y. Drug Metab. Pharmacokinet. (2003)
- The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter. Chen, Y., Kissling, G., Negishi, M., Goldstein, J.A. J. Pharmacol. Exp. Ther. (2005)
- Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. Furuta, S., Kamada, E., Omata, T., Sugimoto, T., Kawabata, Y., Yonezawa, K., Wu, X.C., Kurimoto, T. Eur. J. Pharmacol. (2004)
- Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes. Miyazawa, M., Shindo, M., Shimada, T. Drug Metab. Dispos. (2002)
- Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Michaelis, U.R., Falck, J.R., Schmidt, R., Busse, R., Fleming, I. Arterioscler. Thromb. Vasc. Biol. (2005)
- Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Chang, T.K., Weber, G.F., Crespi, C.L., Waxman, D.J. Cancer Res. (1993)
- Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. Drocourt, L., Ourlin, J.C., Pascussi, J.M., Maurel, P., Vilarem, M.J. J. Biol. Chem. (2002)
- Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. Lasker, J.M., Chen, W.B., Wolf, I., Bloswick, B.P., Wilson, P.D., Powell, P.K. J. Biol. Chem. (2000)
- Intergenic transcripts containing a novel human cytochrome P450 2C exon 1 spliced to sequences from the CYP2C9 gene. Warner, S.C., Finta, C., Zaphiropoulos, P.G. Mol. Biol. Evol. (2001)
- Transcriptional Activation of CYP2C9, CYP1A1, and CYP1A2 by Hepatocyte Nuclear Factor 4{alpha} Requires Coactivators Peroxisomal Proliferator Activated Receptor-{gamma} Coactivator 1{alpha} and Steroid Receptor Coactivator 1. Mart??nez-Jim??nez, C.P., Castell, J.V., G??mez-Lech??n, M.J., Jover, R. Mol. Pharmacol. (2006)
- Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Inoue, K., Yamazaki, H., Imiya, K., Akasaka, S., Guengerich, F.P., Shimada, T. Pharmacogenetics (1997)
- Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity. Flanagan, J.U., McLaughlin, L.A., Paine, M.J., Sutcliffe, M.J., Roberts, G.C., Wolf, C.R. Biochem. J. (2003)